FTC Regulation of Health and Supplement Claims

The Federal Trade Commission holds primary authority over advertising claims made for health products, dietary supplements, and wellness services sold to U.S. consumers. This page covers the legal standards that govern permissible claims, the mechanisms the FTC uses to investigate and challenge deceptive advertising, scenarios that commonly trigger enforcement, and the boundaries between lawful and unlawful representations. Understanding this framework matters because civil penalties for substantiated violations can reach tens of millions of dollars and consent orders impose lasting operational constraints on advertisers.

Definition and scope

FTC authority over health and supplement advertising derives principally from Section 5 of the FTC Act, which prohibits unfair or deceptive acts or practices in or affecting commerce (15 U.S.C. § 45). The FTC's jurisdiction covers advertising — including digital, broadcast, print, and influencer-generated content — while the Food and Drug Administration (FDA) governs labeling on product packaging. This division means a supplement company can face separate enforcement actions from both agencies for the same product: the FDA acting on label text, the FTC acting on paid advertising.

The FTC's Policy Statement on Deceptive Acts or Practices establishes that a representation is deceptive when it is likely to mislead a reasonable consumer and is material to purchasing decisions. For health claims, materiality is almost always presumed because such claims directly affect consumer health decisions and expenditures.

The scope extends to:

• Express claims — explicit statements that a product treats, cures, or prevents a disease or condition
• Implied claims — imagery, testimonials, or juxtapositions that convey a health benefit without stating it directly
• Efficacy claims — assertions about the degree or speed of a product's effect
• Safety claims — representations that a product is safe, natural, or free of harmful ingredients

How it works

The FTC's substantiation standard for health claims requires that advertisers possess competent and reliable scientific evidence before making a claim — not after a complaint is filed. The FTC's Dietary Supplements: An Advertising Guide for Industry specifies that for claims implying disease treatment or prevention, competent and reliable scientific evidence generally means randomized, controlled human clinical trials. For more modest structure/function claims, well-designed studies may suffice, but anecdote, traditional use, or in vitro data alone are insufficient.

The enforcement sequence typically follows this structure:

1. Complaint or monitoring trigger — The FTC receives consumer complaints, conducts market sweeps, or identifies targets through its Consumer Sentinel Network.
2. Investigation — Staff issue civil investigative demands (CIDs) requesting documents, substantiation files, sales data, and communications (FTC Civil Investigative Demands).
3. Staff assessment — Attorneys evaluate whether the advertiser's evidence meets the applicable substantiation standard.
4. Negotiation or litigation — The FTC may negotiate a consent order or file an administrative complaint. In cases of ongoing consumer harm, the agency may seek a federal court injunction.
5. Remedies — Outcomes can include injunctive relief, mandatory substantiation provisions, monetary redress, and civil penalties for order violations (FTC Penalties and Remedies).

The FTC also coordinates with the FDA through a 1971 liaison agreement that allocates primary jurisdiction and prevents duplicative enforcement actions, though both agencies can and do act on the same product category when their respective domains are implicated.

Common scenarios

Three scenarios account for the majority of FTC supplement enforcement actions.

Disease claim advertising. A company markets an herbal extract with claims that it "reverses cognitive decline" or "eliminates type 2 diabetes symptoms." These are disease claims under both FTC and FDA standards. The FTC has brought major actions against companies marketing products for cancer, Alzheimer's disease, and COVID-19 — including a 2020 sweep targeting over 300 companies making unsubstantiated COVID-19 claims, documented in the FTC's public warning letter database at ftc.gov/coronavirus.

Testimonial and endorsement misuse. Companies feature consumer testimonials claiming dramatic weight loss — "I lost 47 pounds in 30 days" — without disclosing that results are atypical. The FTC's Endorsement Guides require clear disclosure of material connections and prohibit presenting atypical results as representative outcomes.

Clinically proven" claims without trials. Advertisers use phrases like "clinically proven" or "doctor recommended" supported only by a single small observational study or a paid endorsement. These trigger the substantiation standard because such language implies a level of clinical rigor that the evidence does not meet.

Decision boundaries

The most operationally significant distinction in this area is between structure/function claims and disease claims.

A second critical boundary exists between actionable deception and puffery. Claims that are so general or vague that no reasonable consumer would rely on them as factual — "the world's best supplement" — do not trigger the substantiation requirement. However, once a claim crosses into specific, measurable assertions about health outcomes, the substantiation standard applies regardless of qualifying language like "may" or "helps."

The FTC also distinguishes between prospective compliance and order violations. A first-time advertiser who lacks substantiation faces injunctive relief and possible monetary redress. A company that violates a prior consent order faces civil penalties of up to $51,744 per violation per day (FTC Act § 5(m)), a figure adjusted periodically under the Federal Civil Penalties Inflation Adjustment Act.

For a broader view of how health advertising enforcement fits within the FTC's overall consumer protection mission, the ftcauthority.com index provides context across the agency's full regulatory portfolio.